Secondary Patenting Of Branded Pharmaceuticals: A Case Study Of How Patents On Two HIV Drugs Could Be Extended For Decades-Reference-Cited by-同舟云学术

Secondary Patenting Of Branded Pharmaceuticals: A Case Study Of How Patents On Two HIV Drugs Could Be Extended For Decades

Published:2012-10 Issue:10 Volume:31 Page:2286-2294
ISSN:0278-2715
Container-title:Health Affairs
language:en
Short-container-title:Health Affairs

Author:

Amin Tahir¹,Kesselheim Aaron S.²

Affiliation:

1. Tahir Amin ( ) is cofounder and director of intellectual property at the Initiative for Medicines, Access, and Knowledge (I-MAK), in New York City.

2. Aaron S. Kesselheim is an assistant professor of medicine at Harvard Medical School, in Boston, Massachusetts.

Publisher

Health Affairs (Project Hope)

Subject

Health Policy

Reference22 articles.

1. State Generic Substitution Laws Can Lower Drug Outlays Under Medicaid

2. Medical-Process Patents — Monopolizing the Delivery of Health Care

3. Evergreening: there's life in the old drug yet

4. The Implications of Choice

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The potential impact of the Comprehensive and Progressive Agreement for Trans-Pacific Partnership on Thailand’s hepatitis C treatment program;Globalization and Health;2024-06-13

2. Cambodia's Imminent Graduation from Least Developed Country Status: What Will be the Impact of the TRIPS Agreement on Access to HIV and Hepatitis C Medicines in Cambodia?;International Journal of Social Determinants of Health and Health Services;2024-04-02

3. The impact of an ‘evergreening’ strategy nearing patent expiration on the uptake of biosimilars and public healthcare costs: a case study on the introduction of a second administration form of trastuzumab in The Netherlands;The European Journal of Health Economics;2024-01-08

4. Global Barriers to Accessing Off-Patent Endocrine Therapies: A Renaissance of the Orphan Disease?;The Journal of Clinical Endocrinology & Metabolism;2023-10-17

5. Investing in Ex Ante Regulation: Evidence from Pharmaceutical Patent Examination;American Economic Journal: Economic Policy;2023-08-01